OncoZenge AB (publ)
ONCOZ.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$58.72M
Close$
$-1.01
126.6% downside
Current Fair Value
126.6% downsideOvervalued by 126.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $58.72 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.31 |
| Beta | 1.31 |
| Outstanding Shares | 14,048,068 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -2.18 |
|---|---|
| PEG | -1.85 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$5.84 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$5.96 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About OncoZenge AB (publ)
1 employees
CEO: Stian Kildal OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Ph...